PolyPeptide Group Balance Sheet Health
Financial Health criteria checks 5/6
PolyPeptide Group has a total shareholder equity of €359.9M and total debt of €91.7M, which brings its debt-to-equity ratio to 25.5%. Its total assets and total liabilities are €665.0M and €305.1M respectively.
Key information
25.5%
Debt to equity ratio
€91.72m
Debt
| Interest coverage ratio | n/a |
| Cash | €48.48m |
| Equity | €359.92m |
| Total liabilities | €305.05m |
| Total assets | €664.97m |
Recent financial health updates
PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt
Oct 21
Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?
Jun 19Recent updates
PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price
Nov 11PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt
Oct 21Sentiment Still Eluding PolyPeptide Group AG (VTX:PPGN)
Sep 16Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?
Jun 19Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce
Mar 14PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price
Mar 13PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 18Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings
Mar 23Financial Position Analysis
Short Term Liabilities: PPGN's short term assets (€292.6M) exceed its short term liabilities (€183.6M).
Long Term Liabilities: PPGN's short term assets (€292.6M) exceed its long term liabilities (€121.4M).
Debt to Equity History and Analysis
Debt Level: PPGN's net debt to equity ratio (12%) is considered satisfactory.
Reducing Debt: PPGN's debt to equity ratio has reduced from 30.5% to 25.5% over the past 5 years.
Debt Coverage: PPGN's debt is well covered by operating cash flow (93%).
Interest Coverage: Insufficient data to determine if PPGN's interest payments on its debt are well covered by EBIT.